{"id":12883,"date":"2022-09-07T14:18:00","date_gmt":"2022-09-07T12:18:00","guid":{"rendered":"https:\/\/iph-multisite.berta-bewegt.ch\/?p=12883"},"modified":"2026-03-03T10:51:20","modified_gmt":"2026-03-03T09:51:20","slug":"rapport-sur-le-remboursement-des-medicaments-pour-les-en-fants-atteints-dun-cancer-le-conseil-federal-cree-de-nouveaux-problemes","status":"publish","type":"post","link":"https:\/\/www.interpharma.ch\/fr\/blog\/rapport-sur-le-remboursement-des-medicaments-pour-les-en-fants-atteints-dun-cancer-le-conseil-federal-cree-de-nouveaux-problemes\/","title":{"rendered":"Rapport sur le remboursement des m\u00e9dicaments pour les en-fants atteints d\u2019un cancer: le Conseil f\u00e9d\u00e9ral cr\u00e9e de nouveaux probl\u00e8mes"},"content":{"rendered":"\n<p class=\"is-style-paragraph-lead-text\"><strong>Un rapport adopt\u00e9 aujourd\u2019hui par le Conseil f\u00e9d\u00e9ral aboutit \u00e0 la conclusion qu\u2019il n\u2019y a pas lieu d\u2019agir dans le domaine de la prise en charge dans des cas particuliers pour les enfants atteints d\u2019un cancer. Du point de vue d\u2019Interpharma, ceci est en contradiction avec l\u2019action du Conseil f\u00e9d\u00e9ral. En effet, la r\u00e9vision actuellement en consultation des art. 71a \u00e0 d de l\u2019ordonnance sur l\u2019assurance-maladie (OAMal) met gravement en danger la prise en charge dans des cas particuliers pour les enfants atteints d\u2019un cancer. <\/strong><\/p>\n\n\n\n<p>Le Conseil f\u00e9d\u00e9ral estime qu\u2019il n\u2019est pas n\u00e9cessaire d\u2019agir dans le domaine de la prise en charge des m\u00e9dicaments dans des cas particuliers en oncologie p\u00e9diatrique. Il s\u2019appuie pour cela sur un rapport <a href=\"https:\/\/www.parlament.ch\/fr\/ratsbetrieb\/suche-curia-vista\/geschaeft?AffairId=20184098\">mandat\u00e9 par la CSSS-N<\/a> qu\u2019il a adopt\u00e9 aujourd\u2019hui. Dans le m\u00eame temps, le Conseil f\u00e9d\u00e9ral souligne que, dans le cadre de la r\u00e9vision en cours de l\u2019OAMal, il a propos\u00e9 des mesures pour am\u00e9liorer l\u2019\u00e9galit\u00e9 de traitement dans le domaine de la prise en charge dans des cas particuliers. Du point de vue d\u2019Interpharma, l\u2019association des entreprises pharmaceutiques pratiquant la recherche, cette argumentation est contradictoire. En effet, dans la r\u00e9vision de l\u2019OAMal, le Conseil f\u00e9d\u00e9ral veut introduire, pour la prise en charge dans des cas particuliers, une prise en compte d\u2019essais cliniques contr\u00f4l\u00e9s d\u00e9montrant un \u00abprogr\u00e8s th\u00e9rapeutique\u00bb d\u2019au moins 35%. \u00c9tant donn\u00e9 que, particuli\u00e8rement dans les situations de cas particuliers d\u2019enfants atteints d\u2019un cancer, on ne dispose souvent pas d\u2019essais cliniques contr\u00f4l\u00e9s, il sera dans la plupart des cas impossible d\u2019apporter cette preuve. La majeure partie des traitements hors \u00e9tiquette ne pourraient alors plus \u00eatre pris en charge et les patient-e-s concern\u00e9-e-s perdraient l\u2019acc\u00e8s au traitement dont ils\/elles ont besoin. Dans son rapport, le Conseil f\u00e9d\u00e9ral n\u2019a donc pas tenu compte de l\u2019impact des propositions qu\u2019il fait.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-proposition-d-interpharma-rendrait-la-revision-inutile\"><strong>Proposition d\u2019Interpharma rendrait la r\u00e9vision inutile<\/strong><strong><\/strong><\/h2>\n\n\n\n<p>Pour les entreprises pharmaceutiques pratiquant la recherche, le bien des patient-e-s est au premier plan. Comme le montre l\u2019exemple ci-dessus, la r\u00e9vision de l\u2019OAMal\/OPAS propos\u00e9e par le Conseil f\u00e9d\u00e9ral est en revanche inad\u00e9quate \u00e0 tous points de vue pour les patient-e-s de Suisse. Nous avons besoin d\u2019une approche qui tienne compte des besoins des malades et am\u00e9liore durablement les conditions cadres de leur acc\u00e8s aux m\u00e9dicaments en Suisse. Par son <a href=\"https:\/\/interpharma.ch\/fr\/blog\/medienmitteilung-interpharma-schlaegt-einen-rueckvergueteten-innovationszugang-fuer-patientinnen-und-patienten-vor\/?lang=fr\">concept de remboursement de l\u2019acc\u00e8s acc\u00e9l\u00e9r\u00e9 des patient-e-s \u00e0 l\u2019innovation<\/a>, Interpharma a pr\u00e9sent\u00e9 d\u00e8s mai une proposition concr\u00e8te.<\/p>\n\n\n\n<blockquote class=\"wp-block-quote has-text-align-center is-layout-flow wp-block-quote-is-layout-flow\"><p>Ren\u00e9 Buholzer, directeur d\u2019Interpharma, d\u00e9clare \u00e0 ce sujet:<br><em>\u00abIl est contradictoire que la Conf\u00e9d\u00e9ration ne voie pas de n\u00e9cessit\u00e9 d\u2019agir au niveau de l\u2019acc\u00e8s aux m\u00e9dicaments pour les enfants atteints d\u2019un cancer, alors qu\u2019il le sape justement par sa r\u00e9vision en cours de l\u2019OAMal. Nous avons besoin de solutions plus ad\u00e9quates que les propositions mises en consultation, et ces solutions existent.\u00bb<\/em><\/p><\/blockquote>\n","protected":false},"excerpt":{"rendered":"<p>Un rapport adopt\u00e9 aujourd\u2019hui par le Conseil f\u00e9d\u00e9ral aboutit \u00e0 la conclusion qu\u2019il n\u2019y a pas lieu d\u2019agir dans le domaine de la prise en charge dans des cas particuliers pour les enfants atteints d\u2019un cancer. Du point de vue d\u2019Interpharma, ceci est en contradiction avec l\u2019action du Conseil f\u00e9d\u00e9ral. En effet, la r\u00e9vision actuellement [&hellip;]<\/p>\n","protected":false},"author":1,"featured_media":14390,"comment_status":"closed","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"inline_featured_image":false,"footnotes":""},"tags":[54,122,131],"class_list":["post-12883","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","tag-medien-fr","tag-communique-de-presse","tag-politique"],"acf":[],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v27.2 (Yoast SEO v27.2) - https:\/\/yoast.com\/product\/yoast-seo-premium-wordpress\/ -->\n<title>Rapport sur le remboursement des m\u00e9dicaments pour les en-fants atteints d\u2019un cancer: le Conseil f\u00e9d\u00e9ral cr\u00e9e de nouveaux probl\u00e8mes - Interpharma<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.interpharma.ch\/fr\/blog\/rapport-sur-le-remboursement-des-medicaments-pour-les-en-fants-atteints-dun-cancer-le-conseil-federal-cree-de-nouveaux-problemes\/\" \/>\n<meta property=\"og:locale\" content=\"fr_FR\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Rapport sur le remboursement des m\u00e9dicaments pour les en-fants atteints d\u2019un cancer: le Conseil f\u00e9d\u00e9ral cr\u00e9e de nouveaux probl\u00e8mes\" \/>\n<meta property=\"og:description\" content=\"Un rapport adopt\u00e9 aujourd\u2019hui par le Conseil f\u00e9d\u00e9ral aboutit \u00e0 la conclusion qu\u2019il n\u2019y a pas lieu d\u2019agir dans le domaine de la prise en charge dans des cas particuliers pour les enfants atteints d\u2019un cancer. Du point de vue d\u2019Interpharma, ceci est en contradiction avec l\u2019action du Conseil f\u00e9d\u00e9ral. En effet, la r\u00e9vision actuellement [&hellip;]\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.interpharma.ch\/fr\/blog\/rapport-sur-le-remboursement-des-medicaments-pour-les-en-fants-atteints-dun-cancer-le-conseil-federal-cree-de-nouveaux-problemes\/\" \/>\n<meta property=\"og:site_name\" content=\"Interpharma\" \/>\n<meta property=\"article:published_time\" content=\"2022-09-07T12:18:00+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2026-03-03T09:51:20+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.interpharma.ch\/wp-content\/uploads\/2022\/09\/iStock-1064859060-1-scaled.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"2560\" \/>\n\t<meta property=\"og:image:height\" content=\"1655\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"berta_admin\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:creator\" content=\"@interpharma_ch\" \/>\n<meta name=\"twitter:site\" content=\"@interpharma_ch\" \/>\n<meta name=\"twitter:label1\" content=\"\u00c9crit par\" \/>\n\t<meta name=\"twitter:data1\" content=\"berta_admin\" \/>\n\t<meta name=\"twitter:label2\" content=\"Dur\u00e9e de lecture estim\u00e9e\" \/>\n\t<meta name=\"twitter:data2\" content=\"3 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\/\/www.interpharma.ch\/fr\/blog\/rapport-sur-le-remboursement-des-medicaments-pour-les-en-fants-atteints-dun-cancer-le-conseil-federal-cree-de-nouveaux-problemes\/#article\",\"isPartOf\":{\"@id\":\"https:\/\/www.interpharma.ch\/fr\/blog\/rapport-sur-le-remboursement-des-medicaments-pour-les-en-fants-atteints-dun-cancer-le-conseil-federal-cree-de-nouveaux-problemes\/\"},\"author\":{\"name\":\"berta_admin\",\"@id\":\"https:\/\/www.interpharma.ch\/#\/schema\/person\/1302f3da278bb3f8995756877d107818\"},\"headline\":\"Rapport sur le remboursement des m\u00e9dicaments pour les en-fants atteints d\u2019un cancer: le Conseil f\u00e9d\u00e9ral cr\u00e9e de nouveaux probl\u00e8mes\",\"datePublished\":\"2022-09-07T12:18:00+00:00\",\"dateModified\":\"2026-03-03T09:51:20+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\/\/www.interpharma.ch\/fr\/blog\/rapport-sur-le-remboursement-des-medicaments-pour-les-en-fants-atteints-dun-cancer-le-conseil-federal-cree-de-nouveaux-problemes\/\"},\"wordCount\":567,\"publisher\":{\"@id\":\"https:\/\/www.interpharma.ch\/#organization\"},\"image\":{\"@id\":\"https:\/\/www.interpharma.ch\/fr\/blog\/rapport-sur-le-remboursement-des-medicaments-pour-les-en-fants-atteints-dun-cancer-le-conseil-federal-cree-de-nouveaux-problemes\/#primaryimage\"},\"thumbnailUrl\":\"https:\/\/www.interpharma.ch\/wp-content\/uploads\/2022\/09\/iStock-1064859060-1-scaled.jpg\",\"keywords\":[\"M\u00e9dias\",\"Communiqu\u00e9 de presse\",\"Politique\"],\"inLanguage\":\"fr-FR\",\"copyrightYear\":\"2022\",\"copyrightHolder\":{\"@id\":\"https:\/\/www.interpharma.ch\/#organization\"}},{\"@type\":\"WebPage\",\"@id\":\"https:\/\/www.interpharma.ch\/fr\/blog\/rapport-sur-le-remboursement-des-medicaments-pour-les-en-fants-atteints-dun-cancer-le-conseil-federal-cree-de-nouveaux-problemes\/\",\"url\":\"https:\/\/www.interpharma.ch\/fr\/blog\/rapport-sur-le-remboursement-des-medicaments-pour-les-en-fants-atteints-dun-cancer-le-conseil-federal-cree-de-nouveaux-problemes\/\",\"name\":\"Rapport sur le remboursement des m\u00e9dicaments pour les en-fants atteints d\u2019un cancer: le Conseil f\u00e9d\u00e9ral cr\u00e9e de nouveaux probl\u00e8mes - Interpharma\",\"isPartOf\":{\"@id\":\"https:\/\/www.interpharma.ch\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\/\/www.interpharma.ch\/fr\/blog\/rapport-sur-le-remboursement-des-medicaments-pour-les-en-fants-atteints-dun-cancer-le-conseil-federal-cree-de-nouveaux-problemes\/#primaryimage\"},\"image\":{\"@id\":\"https:\/\/www.interpharma.ch\/fr\/blog\/rapport-sur-le-remboursement-des-medicaments-pour-les-en-fants-atteints-dun-cancer-le-conseil-federal-cree-de-nouveaux-problemes\/#primaryimage\"},\"thumbnailUrl\":\"https:\/\/www.interpharma.ch\/wp-content\/uploads\/2022\/09\/iStock-1064859060-1-scaled.jpg\",\"datePublished\":\"2022-09-07T12:18:00+00:00\",\"dateModified\":\"2026-03-03T09:51:20+00:00\",\"breadcrumb\":{\"@id\":\"https:\/\/www.interpharma.ch\/fr\/blog\/rapport-sur-le-remboursement-des-medicaments-pour-les-en-fants-atteints-dun-cancer-le-conseil-federal-cree-de-nouveaux-problemes\/#breadcrumb\"},\"inLanguage\":\"fr-FR\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/www.interpharma.ch\/fr\/blog\/rapport-sur-le-remboursement-des-medicaments-pour-les-en-fants-atteints-dun-cancer-le-conseil-federal-cree-de-nouveaux-problemes\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"fr-FR\",\"@id\":\"https:\/\/www.interpharma.ch\/fr\/blog\/rapport-sur-le-remboursement-des-medicaments-pour-les-en-fants-atteints-dun-cancer-le-conseil-federal-cree-de-nouveaux-problemes\/#primaryimage\",\"url\":\"https:\/\/www.interpharma.ch\/wp-content\/uploads\/2022\/09\/iStock-1064859060-1-scaled.jpg\",\"contentUrl\":\"https:\/\/www.interpharma.ch\/wp-content\/uploads\/2022\/09\/iStock-1064859060-1-scaled.jpg\",\"width\":2560,\"height\":1655,\"caption\":\"Shot of a little girl getting a checkup from a pediatrician\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/www.interpharma.ch\/fr\/blog\/rapport-sur-le-remboursement-des-medicaments-pour-les-en-fants-atteints-dun-cancer-le-conseil-federal-cree-de-nouveaux-problemes\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Startseite\",\"item\":\"https:\/\/www.interpharma.ch\/fr\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Rapport sur le remboursement des m\u00e9dicaments pour les en-fants atteints d\u2019un cancer: le Conseil f\u00e9d\u00e9ral cr\u00e9e de nouveaux probl\u00e8mes\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/www.interpharma.ch\/#website\",\"url\":\"https:\/\/www.interpharma.ch\/\",\"name\":\"Interpharma\",\"description\":\"Verband der forschenden Pharmazeutischen Firmen\",\"publisher\":{\"@id\":\"https:\/\/www.interpharma.ch\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/www.interpharma.ch\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"fr-FR\"},{\"@type\":\"Organization\",\"@id\":\"https:\/\/www.interpharma.ch\/#organization\",\"name\":\"Interpharma\",\"url\":\"https:\/\/www.interpharma.ch\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"fr-FR\",\"@id\":\"https:\/\/www.interpharma.ch\/#\/schema\/logo\/image\/\",\"url\":\"https:\/\/interpharma.ch\/wp-content\/uploads\/2026\/03\/20251014_iph_logo_wort_bildmarke_rgb_final_cu01.svg\",\"contentUrl\":\"https:\/\/interpharma.ch\/wp-content\/uploads\/2026\/03\/20251014_iph_logo_wort_bildmarke_rgb_final_cu01.svg\",\"width\":\"1200\",\"height\":\"1200\",\"caption\":\"Interpharma\"},\"image\":{\"@id\":\"https:\/\/www.interpharma.ch\/#\/schema\/logo\/image\/\"},\"sameAs\":[\"https:\/\/x.com\/interpharma_ch\",\"https:\/\/ch.linkedin.com\/company\/interpharma\",\"https:\/\/www.instagram.com\/interpharma_ch\/\"]},{\"@type\":\"Person\",\"@id\":\"https:\/\/www.interpharma.ch\/#\/schema\/person\/1302f3da278bb3f8995756877d107818\",\"name\":\"berta_admin\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"fr-FR\",\"@id\":\"https:\/\/secure.gravatar.com\/avatar\/a2aeb00900e30743ff2859dfc3dd11cf7e64bb4ec7a1f349ee3772658a1d087d?s=96&d=mm&r=g\",\"url\":\"https:\/\/secure.gravatar.com\/avatar\/a2aeb00900e30743ff2859dfc3dd11cf7e64bb4ec7a1f349ee3772658a1d087d?s=96&d=mm&r=g\",\"contentUrl\":\"https:\/\/secure.gravatar.com\/avatar\/a2aeb00900e30743ff2859dfc3dd11cf7e64bb4ec7a1f349ee3772658a1d087d?s=96&d=mm&r=g\",\"caption\":\"berta_admin\"},\"sameAs\":[\"https:\/\/interpharma.ch\"]}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Rapport sur le remboursement des m\u00e9dicaments pour les en-fants atteints d\u2019un cancer: le Conseil f\u00e9d\u00e9ral cr\u00e9e de nouveaux probl\u00e8mes - Interpharma","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.interpharma.ch\/fr\/blog\/rapport-sur-le-remboursement-des-medicaments-pour-les-en-fants-atteints-dun-cancer-le-conseil-federal-cree-de-nouveaux-problemes\/","og_locale":"fr_FR","og_type":"article","og_title":"Rapport sur le remboursement des m\u00e9dicaments pour les en-fants atteints d\u2019un cancer: le Conseil f\u00e9d\u00e9ral cr\u00e9e de nouveaux probl\u00e8mes","og_description":"Un rapport adopt\u00e9 aujourd\u2019hui par le Conseil f\u00e9d\u00e9ral aboutit \u00e0 la conclusion qu\u2019il n\u2019y a pas lieu d\u2019agir dans le domaine de la prise en charge dans des cas particuliers pour les enfants atteints d\u2019un cancer. Du point de vue d\u2019Interpharma, ceci est en contradiction avec l\u2019action du Conseil f\u00e9d\u00e9ral. En effet, la r\u00e9vision actuellement [&hellip;]","og_url":"https:\/\/www.interpharma.ch\/fr\/blog\/rapport-sur-le-remboursement-des-medicaments-pour-les-en-fants-atteints-dun-cancer-le-conseil-federal-cree-de-nouveaux-problemes\/","og_site_name":"Interpharma","article_published_time":"2022-09-07T12:18:00+00:00","article_modified_time":"2026-03-03T09:51:20+00:00","og_image":[{"width":2560,"height":1655,"url":"https:\/\/www.interpharma.ch\/wp-content\/uploads\/2022\/09\/iStock-1064859060-1-scaled.jpg","type":"image\/jpeg"}],"author":"berta_admin","twitter_card":"summary_large_image","twitter_creator":"@interpharma_ch","twitter_site":"@interpharma_ch","twitter_misc":{"\u00c9crit par":"berta_admin","Dur\u00e9e de lecture estim\u00e9e":"3 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.interpharma.ch\/fr\/blog\/rapport-sur-le-remboursement-des-medicaments-pour-les-en-fants-atteints-dun-cancer-le-conseil-federal-cree-de-nouveaux-problemes\/#article","isPartOf":{"@id":"https:\/\/www.interpharma.ch\/fr\/blog\/rapport-sur-le-remboursement-des-medicaments-pour-les-en-fants-atteints-dun-cancer-le-conseil-federal-cree-de-nouveaux-problemes\/"},"author":{"name":"berta_admin","@id":"https:\/\/www.interpharma.ch\/#\/schema\/person\/1302f3da278bb3f8995756877d107818"},"headline":"Rapport sur le remboursement des m\u00e9dicaments pour les en-fants atteints d\u2019un cancer: le Conseil f\u00e9d\u00e9ral cr\u00e9e de nouveaux probl\u00e8mes","datePublished":"2022-09-07T12:18:00+00:00","dateModified":"2026-03-03T09:51:20+00:00","mainEntityOfPage":{"@id":"https:\/\/www.interpharma.ch\/fr\/blog\/rapport-sur-le-remboursement-des-medicaments-pour-les-en-fants-atteints-dun-cancer-le-conseil-federal-cree-de-nouveaux-problemes\/"},"wordCount":567,"publisher":{"@id":"https:\/\/www.interpharma.ch\/#organization"},"image":{"@id":"https:\/\/www.interpharma.ch\/fr\/blog\/rapport-sur-le-remboursement-des-medicaments-pour-les-en-fants-atteints-dun-cancer-le-conseil-federal-cree-de-nouveaux-problemes\/#primaryimage"},"thumbnailUrl":"https:\/\/www.interpharma.ch\/wp-content\/uploads\/2022\/09\/iStock-1064859060-1-scaled.jpg","keywords":["M\u00e9dias","Communiqu\u00e9 de presse","Politique"],"inLanguage":"fr-FR","copyrightYear":"2022","copyrightHolder":{"@id":"https:\/\/www.interpharma.ch\/#organization"}},{"@type":"WebPage","@id":"https:\/\/www.interpharma.ch\/fr\/blog\/rapport-sur-le-remboursement-des-medicaments-pour-les-en-fants-atteints-dun-cancer-le-conseil-federal-cree-de-nouveaux-problemes\/","url":"https:\/\/www.interpharma.ch\/fr\/blog\/rapport-sur-le-remboursement-des-medicaments-pour-les-en-fants-atteints-dun-cancer-le-conseil-federal-cree-de-nouveaux-problemes\/","name":"Rapport sur le remboursement des m\u00e9dicaments pour les en-fants atteints d\u2019un cancer: le Conseil f\u00e9d\u00e9ral cr\u00e9e de nouveaux probl\u00e8mes - Interpharma","isPartOf":{"@id":"https:\/\/www.interpharma.ch\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.interpharma.ch\/fr\/blog\/rapport-sur-le-remboursement-des-medicaments-pour-les-en-fants-atteints-dun-cancer-le-conseil-federal-cree-de-nouveaux-problemes\/#primaryimage"},"image":{"@id":"https:\/\/www.interpharma.ch\/fr\/blog\/rapport-sur-le-remboursement-des-medicaments-pour-les-en-fants-atteints-dun-cancer-le-conseil-federal-cree-de-nouveaux-problemes\/#primaryimage"},"thumbnailUrl":"https:\/\/www.interpharma.ch\/wp-content\/uploads\/2022\/09\/iStock-1064859060-1-scaled.jpg","datePublished":"2022-09-07T12:18:00+00:00","dateModified":"2026-03-03T09:51:20+00:00","breadcrumb":{"@id":"https:\/\/www.interpharma.ch\/fr\/blog\/rapport-sur-le-remboursement-des-medicaments-pour-les-en-fants-atteints-dun-cancer-le-conseil-federal-cree-de-nouveaux-problemes\/#breadcrumb"},"inLanguage":"fr-FR","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.interpharma.ch\/fr\/blog\/rapport-sur-le-remboursement-des-medicaments-pour-les-en-fants-atteints-dun-cancer-le-conseil-federal-cree-de-nouveaux-problemes\/"]}]},{"@type":"ImageObject","inLanguage":"fr-FR","@id":"https:\/\/www.interpharma.ch\/fr\/blog\/rapport-sur-le-remboursement-des-medicaments-pour-les-en-fants-atteints-dun-cancer-le-conseil-federal-cree-de-nouveaux-problemes\/#primaryimage","url":"https:\/\/www.interpharma.ch\/wp-content\/uploads\/2022\/09\/iStock-1064859060-1-scaled.jpg","contentUrl":"https:\/\/www.interpharma.ch\/wp-content\/uploads\/2022\/09\/iStock-1064859060-1-scaled.jpg","width":2560,"height":1655,"caption":"Shot of a little girl getting a checkup from a pediatrician"},{"@type":"BreadcrumbList","@id":"https:\/\/www.interpharma.ch\/fr\/blog\/rapport-sur-le-remboursement-des-medicaments-pour-les-en-fants-atteints-dun-cancer-le-conseil-federal-cree-de-nouveaux-problemes\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Startseite","item":"https:\/\/www.interpharma.ch\/fr\/"},{"@type":"ListItem","position":2,"name":"Rapport sur le remboursement des m\u00e9dicaments pour les en-fants atteints d\u2019un cancer: le Conseil f\u00e9d\u00e9ral cr\u00e9e de nouveaux probl\u00e8mes"}]},{"@type":"WebSite","@id":"https:\/\/www.interpharma.ch\/#website","url":"https:\/\/www.interpharma.ch\/","name":"Interpharma","description":"Verband der forschenden Pharmazeutischen Firmen","publisher":{"@id":"https:\/\/www.interpharma.ch\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.interpharma.ch\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"fr-FR"},{"@type":"Organization","@id":"https:\/\/www.interpharma.ch\/#organization","name":"Interpharma","url":"https:\/\/www.interpharma.ch\/","logo":{"@type":"ImageObject","inLanguage":"fr-FR","@id":"https:\/\/www.interpharma.ch\/#\/schema\/logo\/image\/","url":"https:\/\/interpharma.ch\/wp-content\/uploads\/2026\/03\/20251014_iph_logo_wort_bildmarke_rgb_final_cu01.svg","contentUrl":"https:\/\/interpharma.ch\/wp-content\/uploads\/2026\/03\/20251014_iph_logo_wort_bildmarke_rgb_final_cu01.svg","width":"1200","height":"1200","caption":"Interpharma"},"image":{"@id":"https:\/\/www.interpharma.ch\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/x.com\/interpharma_ch","https:\/\/ch.linkedin.com\/company\/interpharma","https:\/\/www.instagram.com\/interpharma_ch\/"]},{"@type":"Person","@id":"https:\/\/www.interpharma.ch\/#\/schema\/person\/1302f3da278bb3f8995756877d107818","name":"berta_admin","image":{"@type":"ImageObject","inLanguage":"fr-FR","@id":"https:\/\/secure.gravatar.com\/avatar\/a2aeb00900e30743ff2859dfc3dd11cf7e64bb4ec7a1f349ee3772658a1d087d?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a2aeb00900e30743ff2859dfc3dd11cf7e64bb4ec7a1f349ee3772658a1d087d?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a2aeb00900e30743ff2859dfc3dd11cf7e64bb4ec7a1f349ee3772658a1d087d?s=96&d=mm&r=g","caption":"berta_admin"},"sameAs":["https:\/\/interpharma.ch"]}]}},"_links":{"self":[{"href":"https:\/\/www.interpharma.ch\/fr\/wp-json\/wp\/v2\/posts\/12883","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.interpharma.ch\/fr\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.interpharma.ch\/fr\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.interpharma.ch\/fr\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.interpharma.ch\/fr\/wp-json\/wp\/v2\/comments?post=12883"}],"version-history":[{"count":2,"href":"https:\/\/www.interpharma.ch\/fr\/wp-json\/wp\/v2\/posts\/12883\/revisions"}],"predecessor-version":[{"id":14392,"href":"https:\/\/www.interpharma.ch\/fr\/wp-json\/wp\/v2\/posts\/12883\/revisions\/14392"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.interpharma.ch\/fr\/wp-json\/wp\/v2\/media\/14390"}],"wp:attachment":[{"href":"https:\/\/www.interpharma.ch\/fr\/wp-json\/wp\/v2\/media?parent=12883"}],"wp:term":[{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.interpharma.ch\/fr\/wp-json\/wp\/v2\/tags?post=12883"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}